Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase Safety and Efficacy in Pediatric NHL and Acute Leukemia in China
CTR20200041Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of rasburicase in hyperuricemia, non-Hodgkin lymphoma (NHL), Acute Leukaemia, sponsored by Sanofi. Started Apr 2020; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemianon-Hodgkin lymphoma (NHL)Acute Leukaemia
Beyond the preview
Go deeper on CTR20200041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200041.